~~<i id='6F2661ACE2'><strike id='6F2661ACE2'><tt id='6F2661ACE2'><pre id='6F2661ACE2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

fashion

author：leisure time 2025-09-07 17:29:56 - browse：13

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： New weight loss drugs work. But how can they best be used?

hotspot

focus

leisure time

focus

hotspot

BirdfluparticlesNIAIDVivienDuganisn’tgettingmuchsleepthesedays.Thedirectoroftheinfluenzadivisionatth

WSS

White House finalizes ITC's import ban of latest Apple Watches

Videos point to link between seizures and unexplained toddler deaths

New weight loss drugs work. But how can they best be used?

The White House hikes tariffs on plastic syringes made in China

WuXi Biologics beefs up its lobbying operation

The biotech scorecard for Q1: 17 stock

Wikipedia

fashion

hotspot

Medicare details structure of new drug price negotiation program

Fertility clinic egg and embryo storage is a disaster

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WuXi Biologics execs register to lobby as Congress comes for the company

Affirmative action in medical school literally saved lives

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Malaria cases in Florida and Texas: Here’s what you need to know

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Cancer drug shortages should be causing more outrage

AdventHealth escalates lawsuit against insurance vendor Multiplan

focus

STAT series 'Denied by AI' wins major journalism prizes

Goldman Sachs launches $650M fund for life science investments

Ahead of JPM, here's who's profiting most in health care

STAT reporters are Pulitzer Prize finalists for investigative reporting

CVS is willing to dump 10% of its Medicare Advantage members

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

leisure time

focus

hotspot

hotspot